Skip to content

Study · Not a test of the peptide alone · 2024

2 results

Role of GLP1-RA in Optimizing Weight Loss Post-Bariatric Surgery: A Systematic Review and Meta-Analysis.

Pereira M, Menezes S, Franco AJ, Marcolin P, Tomera M

Obesity surgery31 Aug 2024Cited by 10 (Europe PMC)

PMID39215779 (opens in a new tab)DOI10.1007/s11695-024-07486-w (opens in a new tab)PepBankPUB-39215779
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In patients after bariatric surgery, pooled GLP1-RA therapy (particularly liraglutide 1.8-3 mg) significantly reduced mean BMI at six months versus placebo.

    In plain wordsAfter bariatric surgery, a group of GLP1-RA drugs, particularly liraglutide, lowered BMI more than placebo at six months.

    Peptide
    Liraglutide
    Outcome
    DecreaseMean BMI at six months
    Study

    n = 130

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    GLP1-RA therapy, particularly liraglutide (1.8-3 mg), significantly reduced mean BMI and body weight percentage at six months.
    1 context sentence
    Summary · context
    By systematically reviewing and analyzing data from three randomized controlled trials (RCTs) involving 130 patients

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In patients after bariatric surgery, pooled GLP1-RA therapy (particularly liraglutide 1.8-3 mg) significantly reduced body weight percentage at six months versus placebo.

    In plain wordsAfter bariatric surgery, a group of GLP1-RA drugs, particularly liraglutide, lowered body weight percentage more than placebo at six months.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight percentage at six months
    Study

    n = 130

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    GLP1-RA therapy, particularly liraglutide (1.8-3 mg), significantly reduced mean BMI and body weight percentage at six months.
    1 context sentence
    Summary · context
    By systematically reviewing and analyzing data from three randomized controlled trials (RCTs) involving 130 patients

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.